ASH Conference Coverage
Latest Articles
(MedPage Today) Dec 8, 2016 - Two-thirds of patients with proteasome inhibitor-refractory myeloma responded to the antiretroviral agent nelfinavir, added to standard myeloma agents, according to a small study reported here.
Read Article
(labiotech.eu) Dec 6, 2016 - From leukemia to multiple myeloma, biotech is working hard to cure blood cancer. This year’s edition of the American Society of Hematology (ASH) annual meeting features immuno-oncology therapies developed by the best European biotechs, with Novartis taking the lead in the CAR-T field.
Read Article
More Articles
December 07, 2016
December 07, 2016
December 07, 2016
December 07, 2016
December 07, 2016
December 07, 2016
December 07, 2016
December 07, 2016
View More
News Commentary
There is no ASH Conference Coverage commentary.

OBR Blog
By Lynne Lederman, PhD At this past December’s American Society of Hematology (ASH) annual meeting, the late-breaking... Read more
January 17, 2017
Introduction Presenting you with timely market feedback from the 58th ASH Annual Meeting held in December 2016, OBR and... Read more
January 17, 2017